Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6455678

Title:Human hematopoietic stem and progenitor cell antigen
Inventors:Yin, Amy H.; San Jose, CA, USA
Miraglia, Sheri; Palo Alto, CA, USA
Godfry, Wayne G.; Atherton, CA, USA
Buck, David W.; Santa Clara, CA, USA
Summary:This invention describes an antibody specific for the hematopoietic stem and progenitor cell antigen, AC133. Described herein are a hematopoietic progenitor cell antigen and reagents, namely antibodies, that specifically bind to the antigen. Central to the invention is the concept that antigen expression is highly tissue-specific, and is only detectable on a subset of hematopoietic progenitor cells that have been derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. Further disclosed herein is the CD34bright subset of cells recognized by AC133 and containing substantially all of the CFU-GM activity present in the CD34+ population, the highly specific distribution of which is described as allowing the use of AC133 as a reagent for the isolation and characterization of human hematopoietic progenitor and stem cells. Also provided are methods by which cells selected for the expression of the AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers. Therapeutic applications as vehicles of gene therapy and for bone marrow reconstitution are included.
Abstract:A hematopoietic progenitor cell antigen and reagents, notably antibodies, that specifically bind to the antigen are provided. Expression of the antigen is highly tissue specific. It is only detected on a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood. The subset of cells recognized by AC133 is CD34.sup.bright and contains substantially all of the CFU-GM activity present in the CD34.sup.+ population. This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells. Cells selected for expression of AC133 antigen can be further purified by selection for other hematopoietic stem cell and progenitor cell markers.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6455678
Application Number:US1997000842382
Date Filed:23/04/1997
Date Published:24/09/2002
Assignee:AmCell Corporation, Burlingame, CA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/13/2021